Literature DB >> 24488656

Metabolite ratios in 1H MR spectroscopic imaging of the prostate.

Thiele Kobus1, Alan J Wright1, Elisabeth Weiland2, Arend Heerschap1, Tom W J Scheenen1.   

Abstract

In (1)H MR spectroscopic imaging ((1)H-MRSI) of the prostate the spatial distribution of the signal levels of the metabolites choline, creatine, polyamines, and citrate are assessed. The ratio of choline (plus spermine as the main polyamine) plus creatine over citrate [(Cho+(Spm+)Cr)/Cit] is derived from these metabolites and is used as a marker for the presence of prostate cancer. In this review, the factors that are of importance for the metabolite ratio are discussed. This is relevant, because the appearance of the metabolites in the spectrum depends not only on the underlying anatomy, metabolism, and physiology of the tissue, but also on acquisition parameters. These parameters influence especially the spectral shapes of citrate and spermine resonances, and consequently, the (Cho+(Spm+)Cr)/Cit ratio. Both qualitative and quantitative approaches can be used for the evaluation of (1)H-MRSI spectra of the prostate. For the quantitative approach, the (Cho+(Spm+)Cr)/Cit ratio can be determined by integration or by a fit based on model signals. Using the latter, the influence of the acquisition parameters on citrate can be taken into account. The strong overlap between the choline, creatine, and spermine resonances complicates fitting of the individual metabolites. This overlap and (unknown, possibly tissue-related) variations in T1, T2, and J-modulation hamper the application of corrections needed for a "normalized" (Cho+(Spm+)Cr)/Cit ratio that would enable comparison of spectra measured with different prostate MR spectroscopy protocols. Quantitative (Cho+(Spm+)Cr)/Cit thresholds for the evaluation of prostate cancer are therefore commonly established per institution or per protocol. However, if the same acquisition and postprocessing protocol were used, the ratio and the thresholds would be institution-independent, promoting the clinical usability of prostate (1)H-MRSI.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  1H MRS; Prostate cancer; acquisition protocols; metabolite ratios

Mesh:

Substances:

Year:  2014        PMID: 24488656     DOI: 10.1002/mrm.25122

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  13 in total

Review 1.  Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.

Authors:  Ananthakrishnan Sivaraman; Kulthe Ramesh Seetharam Bhat
Journal:  Indian J Surg Oncol       Date:  2017-01-23

2.  Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion.

Authors:  Lilianne Frégeau-Proulx; Aurélie Lacouture; Line Berthiaume; Cindy Weidmann; Mario Harvey; Kevin Gonthier; Jean-François Pelletier; Bertrand Neveu; Cynthia Jobin; Dominic Bastien; Alain Bergeron; Yves Fradet; Louis Lacombe; Isabelle Laverdière; Chantal Atallah; Frédéric Pouliot; Étienne Audet-Walsh
Journal:  Mol Metab       Date:  2022-05-20       Impact factor: 8.568

3.  The aging effect on prostate metabolite concentrations measured by 1H MR spectroscopy.

Authors:  Monika Dezortova; Filip Jiru; Antonin Skoch; Vaclav Capek; Zuzana Ryznarova; Viktor Vik; Milan Hajek
Journal:  MAGMA       Date:  2016-08-13       Impact factor: 2.310

Review 4.  [Technique of proton and phosphorous MR spectroscopy].

Authors:  M Backens
Journal:  Radiologe       Date:  2017-06       Impact factor: 0.635

5.  Spectral Wavelet-feature Analysis and Classification Assisted Denoising for enhancing magnetic resonance spectroscopy.

Authors:  Bing Ji; Zahra Hosseini; Liya Wang; Lei Zhou; Xinhua Tu; Hui Mao
Journal:  NMR Biomed       Date:  2021-03-09       Impact factor: 4.044

6.  Reproducibility of brain metabolite concentration measurements in lesion free white matter at 1.5 T.

Authors:  Martin H J Busch; Wolfgang Vollmann; Serban Mateiescu; Manuel Stolze; Martin Deli; Marietta Garmer; Dietrich H W Grönemeyer
Journal:  BMC Med Imaging       Date:  2015-09-29       Impact factor: 1.930

7.  Multi-component quantitative magnetic resonance imaging by phasor representation.

Authors:  Frank J Vergeldt; Alena Prusova; Farzad Fereidouni; Herbert van Amerongen; Henk Van As; Tom W J Scheenen; Arjen N Bader
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

Review 8.  Novel tools for prostate cancer prognosis, diagnosis, and follow-up.

Authors:  Andreas Dimakakos; Athanasios Armakolas; Michael Koutsilieris
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

9.  Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.

Authors:  Basetti Madhu; Greg L Shaw; Anne Y Warren; David E Neal; John R Griffiths
Journal:  Metabolomics       Date:  2016-06-30       Impact factor: 4.290

Review 10.  DCE-MRI, DW-MRI, and MRS in Cancer: Challenges and Advantages of Implementing Qualitative and Quantitative Multi-parametric Imaging in the Clinic.

Authors:  Jessica M Winfield; Geoffrey S Payne; Alex Weller; Nandita M deSouza
Journal:  Top Magn Reson Imaging       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.